Close
CDMO Safety Testing 2026
Novotech

Business & Industry

Azerbaijan, Jordan Explore Joint Pharmaceutical Venture

Azerbaijan and Jordan are looking out for new opportunities in order to establish a joint pharmaceutical venture, thereby signalling a very robust step towards much deeper economic cooperation. As per Azernews, this occurrence was highlighted by Yarub Al-Guda, the Jordanian...

India, Switzerland Discuss Pharma and Biotech Collaboration

Piyush Goyal, the Commerce and Industry Minister, met Helene Budliger Artieda, the visiting Swiss State Secretary for Economic Affairs, and discussed cooperation when it comes to research and development as well as pharma and biotech collaboration with a view...

Algeria Showcases its Strength in African Pharma Sector

Abdelmadjid Tebboune, the Algerian president, went on to address participants at the African Ministerial Conference on Local Pharmaceutical Production and Health Technologies on November 27, 2025, with his message being read by Sifi Ghrieb, the prime minister. The event, which...

Eli Lilly Becomes the First Drugmaker to Hit $1tn Valuation

Eli Lilly, the US pharma giant, has become the first drugmaker to hit $1tn valuation on November 22, 2025, hence entering the exclusive club, which is so far dominated by technology giants, highlighting its rise as a weight-loss powerhouse. The...

400 Global Regulatory Manufacturing Approvals for Samsung Biologics

Samsung Biologicsย announced on November 26, 2025,ย that it has gone on to achieve a whopping 400 regulatory manufacturing approvals all over the world due to its quality competitiveness. It is worth noting that as of November 2025, Samsung Biologics has secured...

AstraZeneca, Biopharma Giant, Announces $2bn Investment in Maryland

It should not be termed as an overstatement when we say that Maryland is fast becoming the home away from home when it comes to AstraZeneca, the British drugmaker. On November 21, the biopharma powerhouse pushed it up a...

Australian Biopharma to Expand US Plasma-Derived Therapies

The Australian-based biopharma company, CSL, plans to invest almost $1.5 billion in the next five years so as to expand its presence in the U.S. However, this is going to be subject to the approval from the board of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป